Resumen

GUILLEN CUADROS, Mayra; WITTONG MONTESDEOCA, Raquel; CORNEJO LAGO, Silvia  y  MACIAS ZAMBRANO, Daniel. Compassionate-Use Ruxolitinib for Covid-19 Compared to Treatment with Chloroquines. Report on 100 cases at the Hospital de Especialidades Portoviejo, Ecuador. Rev. am. med. respir. [online]. 2022, vol.22, n.3, pp.298-304. ISSN 1852-236X.  http://dx.doi.org/10.56538/gwfc3776.

The group with compassionate use of ruxolitinib for Covid-19 showed improved chest images and a larger number of discharged patients, compared to group 1 (chloro quines and azithromycin), with a decrease in inflammatory markers. There is one arti cle that described a case which refractory to anti-IL6 therapy but responded to Jak-Stat inhibition with ruxolitinib.1 The most common comorbidity in both groups was arterial hypertension, followed by diabetes type 2; group 1 showed a larger number of patients without comorbidities (18 patients).

The number of male patients with the disease caused by SARS-CoV2 was larger in group 1, with 31 males (62.0%), compared to a total of 19 females (38.0%), whereas in group 2, 25.0% were males, and 25.0% females. The severity of Covid-19 was defined as moderate: adolescent or adult with clinical signs of pneumonia (fever, cough, dys pnea, tachypnea), particularly SpO2 ≥ 90% on ambient air; and severe: adolescent or adult with clinical signs of pneumonia (fever, cough, dyspnea, tachypnea) plus some of the following: respiratory rate > 30 breaths/min, severe respiratory distress or SpO2 < 90% on ambient air.2

The acute respiratory distress syndrome (ARDS) in both groups had an average ratio of pressure arterial oxygen and fraction of inspired oxygen (PaFi) of 135.3 mmHg in the ruxolitinib group versus 138.9 mmHg in the control group.

Efficacy was defined as: decrease in inflammatory markers, gasometric improvement in the PaFi, lower oxygen requirement, lower number of patients with severe symptoms admitted to the Intensive Care Unit, proof of the drug’s safety 10 days after use, and detailed number of discharged patients.

Palabras clave : Ruxolitinib; Infecciones por coronavirus; Citocinas; Síndrome de Dificultad Respiratoria del Adulto; SARS-CoV2; Cloroquinas.

        · resumen en Español     · texto en Inglés     · Inglés ( pdf )